BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/17/2023 6:20:53 AM | Browse: 466 | Download: 1092
 |
Received |
|
2022-09-15 10:13 |
|
Peer-Review Started |
|
2022-09-15 10:16 |
|
First Decision by Editorial Office Director |
|
2022-11-15 08:02 |
|
Return for Revision |
|
2022-11-15 08:02 |
|
Revised |
|
2023-01-06 15:29 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-03-03 03:28 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-03-07 18:47 |
|
Articles in Press |
|
2023-03-07 18:47 |
|
Edit the Manuscript by Language Editor |
|
2023-03-13 00:56 |
|
Typeset the Manuscript |
|
2023-03-14 01:39 |
|
Publish the Manuscript Online |
|
2023-03-17 06:20 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Khansa Ahsan, Munir Ahmad Anwar and Nayla Munawar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nayla Munawar, PhD, Assistant Professor, Chemistry, United Arab Emirates University, College of Science, United Arab Emirates University, Al Ain 15551, United Arab Emirates. nmunawar@uaeu.ac.ae |
| Key Words |
COVID-19; Gut-liver axis; Probiotics; Prebiotics; Cytokines; Gut microbiome |
| Core Tip |
There are several reviews in the literature contributed to the pathophysiology of liver damage during severe acute respiratory syndrome coronavirus 2 infection. However, we highlight the potential role of gut microbiota in managing drug-induced liver damage during and after coronavirus disease 2019 (COVID-19) infection. We shed light on various metabolites produced by gut microorganisms that have a significant role in reducing liver damage in COVID-19 infection with the use of different probiotics and prebiotics. |
| Publish Date |
2023-03-17 06:20 |
| Citation |
Ahsan K, Anwar MA, Munawar N. Gut microbiome therapeutic modulation to alleviate drug-induced hepatic damage in COVID-19 patients. World J Gastroenterol 2023; 29(11): 1708-1720 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i11/1708.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i11.1708 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
